Dagens Industri SV

Ta hotet mot läkemedelsindustrin på allvar

Konsekvenserna av Donald Trumps nya prisreform på läkemedel börjar märkas också i Europa. Den slår både mot tillgängligheten av läkemedel och mot spetsforskningen. I EU-systemet skymtas dessvärre ingen direkt krisinsikt. Men regeringen borde göra mer för att stärka den svenska läkemedelssektorns konkurrenskraft i dagens hårdnande globala konkurrens.

Mar 08, 2026 &03150808202631; 15:15 UTC www.di.se

Read original on www.di.se ↗

↘

Negative for markets

Sentiment score: -65/100

High impact Medium-term (weeks)

WHAT THIS MEANS

Donald Trump's pharmaceutical price reforms are creating ripple effects across Europe, threatening both drug availability and cutting-edge research. The EU lacks a coordinated crisis response, while Sweden's government should strengthen its pharmaceutical sector's competitiveness amid intensifying global competition.

AI CONFIDENCE

75% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

IT→.MI

IT→.MIStock

Expected to decline

Italian pharmaceutical companies exposed to US price pressure and reduced R&D investment

↓

Euro Stoxx 50

^STOXX50EIndex

Expected to decline

European pharmaceutical sector weakness from Trump's pricing reforms affecting major holdings

↓

DAX (Germany)

^GDAXIIndex

Expected to decline

German pharma companies (Bayer, Merck KGaA) negatively impacted by US price controls spillover

↓

EU→.PA

EU→.PAStock

Expected to decline

French pharmaceutical sector faces margin compression from pricing pressure

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider reducing exposure to European pharmaceutical stocks, particularly Italian and German names. Monitor EU policy developments closely; any coordinated support measures could reverse bearish sentiment. Short-term headwinds likely to persist 6-12 months.

KEY SIGNALS

US pharmaceutical price reform creating European market disruptionReduced R&D investment capacity across EU pharma sectorDrug availability concerns emerging in EuropeLack of coordinated EU policy response to crisisCompetitive disadvantage for European pharma vs global players

SECTORS INVOLVED

PharmaceuticalsHealthcareBiotechnologyMedical Research

Analysis generated on Mar 09, 2026 at 16:25 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Dagens Industri. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Ta hotet mot läkemedelsindustrin på allvar

RELATED INTELLIGENCE